Biotech Values

[biotech jim]

I say that the tofacitinib AdComm opinion to be positive by plurality as well. The immune safety issues can be in the label like the oncology risks for Humira et al. Will be interesting the view on the radiology results. Surely there was an FDA dialogue on this as well as with the efficacy endpoints.

BJ